September 23, 2005 09:59 ET

Nymox NicAlert™ Featured in Nevada Tobacco Free Babies Project Presentation

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Sep 23, 2005) -

NicAlert™, Nymox Pharmaceutical Corporation's (NASDAQ: NYMX) innovative product for measuring tobacco use or exposure, was featured as a potential "best practice" for assessing tobacco use or second-hand smoke exposure in a presentation by Dr. Sher Todd at the 3rd annual conference of the Coalition for a Tobacco Free Arizona held on September 8 and 9 in Phoenix, Arizona. Dr. Todd is the Program Manager of the Tobacco Free Babies Project in Reno, Nevada. The conference drew participants from across the U.S. Southwest as well as California.

According to Dr. Todd's presentation, tobacco use and exposure should be routinely assessed as a vital sign like blood pressure or weight, particularly for pregnant women. Research has shown routine assessment of tobacco use or exposure and intervention more than doubled the rate of smoking cessation for pregnant women. NicAlert™ provides their program with an objective biological confirmation of tobacco use or second-hand smoke exposure. Reduction or cessation of tobacco use or second-hand smoke exposure by pregnant women offers both substantial health benefits to both mother and fetus and long-term savings for healthcare programs, providers and payers.

Nymox's NicAlert™ product provides a proven, easy-to-use, on-site means of determining an individual's use of or exposure to tobacco products. The product gives a visual read-out of the level of tobacco use or exposure within minutes and requires no instruments to use. NicAlert™ has received U.S. FDA clearance for medical use for determining an individual's exposure to tobacco products.

NicAlert™ uses powerful, one-step patented technology to measure the level of cotinine, a metabolite of nicotine, in urine. Cotinine is widely accepted and commonly used in medical research and public health studies to determine the extent of tobacco product use or exposure.

Nymox also offers TobacAlert™, which is for non-medical uses and can detect second-hand smoke exposure. TobacAlert™ is available at approximately 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information about TobacAlert™ is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX